Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 4/2020

Open Access 23.01.2020 | Otology

Middle-ear cholesteatoma co-existing with labyrinthine fistula and vestibular schwannoma

verfasst von: Aleksander Zwierz, K. Masna, P. Burduk

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 4/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Many conditions, among them vestibular schwannoma and middle ear cholesteatoma with lateral semicircular canal destruction, may be associated with asymmetrical sensorineural hearing loss (SNHL) and vertigo. However, the probability that these two distinct disease entities causing the same symptoms occur in a single patient is very low, approximately 1 per 28 billion per 1 year.

Methods

We present the case of a 40-year-old male admitted to our clinic because of chronic middle ear inflammation with concomitant tinnitus vertigo, and deafness in the right ear. The patient was diagnosed with lateral semicircular canal fistula caused by middle-ear cholesteatoma and concomitant vestibular schwannoma. Canal wall-down surgery was carried out to remove the cholesteatoma, followed by gamma knife radiosurgery for the vestibular schwannoma.

Results

Vertigo and tinnitus resolved within 3 days after the ear surgery, and gamma knife treatment resulted in the complete involution of the vestibular schwannoma. The patient presented with completely dry middle-ear cavity and no recurrence of the cholesteatoma was observed during a 3-year follow-up.

Conclusion

As the hereby reported condition is very rare, the results cannot be compared with any similar report published previously. Nevertheless, based on the outcome, the treatment strategy seems to be both reasonable and effective.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Asymmetrical sensorineural hearing loss (SNHL) or deafness and vertigo may have many causes, among them vestibular schwannoma (VS) and chronic otitis media with cholesteatoma formation and destruction of the inner ear structures, such as lateral, superior and posterior semicircular canals and promontory [1]. The incidence of cholesteatoma in adults is reported at 9.2 per 100,000 per year [2], and in 2.7–12% of the cases, this condition may eventually lead to the development of labyrinthine fistula [1, 3] Nearly 90% of labyrinthine fistulas caused by cholesteatoma are located in the lateral semicircular canal, and profound SNHL is noted in 15% of the patients [1]. According to various sources, the incidence of VS varies from 12 to 19.4 per 1 million per year [4, 5]. Considering the low incidence of either cholesteatoma or VS, the probability that these two different entities occur in a single patient is very low, approximately 1 per 28 billion per year, which corresponds to one person worldwide every 4 years. To the best of our knowledge, only one case of cholesteatoma and VS occurring in the same patient has been described thus far, albeit not in the same ear. Below, we present the case of a patient with same-side VS and middle-ear cholesteatoma complicated by labyrinthine fistula; we put special emphasis on the available therapeutic options and treatment outcomes.

Case report

A 40-year-old male was referred to our ENT department with chronic otorrhea that started 4 years earlier, as well as with vertigo and tinnitus that began 6 months before the admission. The patient had a long-term history of right-ear hypoacusis which, according to his mother, started at 11 years of age. The otoscopic examination demonstrated subtotal perforation of the tympanic membrane and keratin masses arising from the attic. Lateralization to the left ear was observed during the Weber test, and the patient tested positively for the Hennebert's sign. No signs of facial nerve dysfunction and taste disorders were noted. Tonal audiometry showed complete hearing loss in the right ear (Fig. 1), with no response to otoacoustic emission and auditory brainstem response (ABR) V wave of 90 dB and interlatency of 9 ms.
Computed tomography (CT) demonstrated a solid-cystic mass (17 × 18 × 20 mm) with calcification foci in the right cerebellopontine angle. Moreover, complete opacification of mastoid cells was observed, along with a mass in the tympanic cavity, causing destruction to the lateral semicircular canal (Fig. 2). Magnetic resonance imaging (MRI) confirmed the presence of the characteristic signs of VS in the cerebellopontine angle and cholesteatoma in the right ear (Fig. 3).
The patient underwent canal wall-down surgery with removal of the cholesteatoma. The procedure also included reconstruction of the tympanic membrane and obliteration of the mastoid cavity. Vertigo and tinnitus resolved within several days after the ear surgery.
When the ear cavity healed completely, the patient underwent gamma knife radiosurgery. Control MRI with Gadoteridol contrast agent demonstrated involution of the VS and reduction of the post-contrast enhancement. On otoscopic examination, the ear was completely dry, with no signs of cholesteatoma recurrence (Fig. 4). Currently, the only ailment reported by the patient is intermittent tinnitus occurring while he leans forward and lasting no longer than a few seconds.

Discussion

To the best of our knowledge, this is the first published report on lateral semicircular canal fistula caused by middle-ear cholesteatoma, co-existing with VS in the same ear. The probability that a single patient developed these two conditions that may both result in deafness and vertigo is very low. It is unclear whether deafness and vertigo present in our patient were associated with VS or chronic middle-ear inflammation and resultant lateral semicircular canal fistula, as these symptoms are characteristic for the progress of both conditions mentioned above. Currently, the treatment of choice in chronic middle-ear inflammation with cholesteatoma and semicircular canal fistula development may be canal wall-down procedure with removal of the middle-ear pathologies. Cholesteatoma matrix should be removed completely.
Both our experiences and published data suggest that vertigo may resolve as a consequence of VS treatment. According to literature, up to 80% of patients subjected to gamma knife radiosurgery no longer presented with vertigo [6, 7]. However, early and late vertigo remission rates after subtotal surgical resections of large VS are no greater than 30% and 14%, respectively [8]. Since our patient no longer presented with vertigo and tinnitus after the middle-ear surgery, these ailments were likely associated with the chronic ear inflammation and semicircular canal fistula. SNHL in patients with chronic otitis media and cholesteatoma may not only be caused by the migration of inflammatory mediators or toxins into the inner ear fluid from the inflammation site [1], but can also be a consequence of VS growth. Identification of the hearing loss etiology in such cases can be challenging, and improvement of hearing function is unlikely.
We carefully analyzed available treatment options in the hereby presented case. Three (four?) different strategies of VS management can be used: microsurgical resection, fractionated radiotherapy, stereotactic radiosurgery or "watch and scan" approach, i.e., observation with serial imaging to detect potential growth of the tumor [9]. The most popular methods for surgical resection are translabyrinthine, middle-fossa and retrosigmoid approaches. Each of these methods poses a 0.5% mortality risk [10]. However, non-surgical strategies, such as gamma knife stereotactic radiosurgery or linear acceleration of electrons (LINAC) are gaining growing popularity nowadays in the treatment of medium-sized tumors with diameters between 1 cm and 2–2.5 cm [11]. The "watch and scan" strategy applies to smaller tumors, with no more than 1 cm in diameter [10], as well as to older patients, > 65 years of age. The decision whether to perform the surgical resection is determined not merely by the tumor size, but also patient's age, surgeon's experience and local guidelines [9], and the physician should always discuss all these factors with the patient.
In the hereby presented case, persistent otorrhea made the patient non-eligible for the most commonly performed type of surgical procedure, translabyrinthine resection [9]. Furthermore, the tumor was very big for the hearing–sparing procedure, retrolabyrinthine resection, and the patient already presented with hearing loss. Hence, the available treatment options included middle-fossa approach, retrosigmoid resection, gamma knife radiosurgery and watchful waiting. Recently, a trend to the more frequent application of radiation therapy than surgical resection is observed, with the former used in twice as many patients as the latter [12]. Another argument for the use of radiation therapy is that most neurosurgeons report problems with intraoperative identification of the facial nerve, and hence, prefer incomplete resection of the tumor to avoid an iatrogenic facial palsy [9]. According to literature, the quality of life in patients treated with radiotherapy is satisfactory, and failure rates with progressive growth of the tumor seem to be similar as the overall recurrence rates after the surgical treatment [12, 13]. While complete surgical removal of a small VS can preserve hearing and facial nerve function, it does not eliminate the risk of tinnitus and vertigo [11]; according to Lund–Johansen [11], persistent vertigo has the most detrimental effect on the quality of life in patients after VS resection.
As our patient did not consent for neurosurgery, gamma knife radiosurgery was the only radical treatment option. In line with current recommendations, the stereotactic radiotherapy was preceded by the treatment of chronic ear inflammation. To shorten the recovery time and to facilitate the introduction of gamma knife therapy, we performed canal wall-down procedure as a one-stage cholesteatoma surgery. We have meticulously removed the whole epithelial lining, covered the fistula with temporalis fascia and obliterated the ear cavity with the temporalis muscle to decrease its volume. Such an approach to labyrinthine fistula has been previously recommended by Sagar et al. [14]. No recurrence of cholesteatoma was observed during a 3-year follow-up period, and the patient no longer reported vertigo. Furthermore, complete involution of VS was achieved with gamma knife therapy.

Conclusion

As the hereby reported condition is very rare, our experiences cannot be compared with any similar report published previously. Nevertheless, based on the outcome, the treatment strategy applied in our patient seems to be both reasonable and effective.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Med HNO

Kombi-Abonnement

Mit e.Med HNO erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes HNO, den Premium-Inhalten der HNO-Fachzeitschriften, inklusive einer gedruckten HNO-Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Copeland BJ, Buchman CA (2003) Management of labyrinthine fistulae in chronic ear surgery. Am J Otolaryngol 24(1):51–60CrossRef Copeland BJ, Buchman CA (2003) Management of labyrinthine fistulae in chronic ear surgery. Am J Otolaryngol 24(1):51–60CrossRef
2.
Zurück zum Zitat Olszewska E, Wagner M, Bernal-Sprekelsen M et al (2004) Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 261:6–24CrossRef Olszewska E, Wagner M, Bernal-Sprekelsen M et al (2004) Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 261:6–24CrossRef
3.
Zurück zum Zitat Letícia PSR, Canali I, Teixeira A, Silva MN, Selaimen F, da Costa SS (2010) Cholesteatoma labyrinthine fistula: prevalence and impact. Neurosurgery 67(5):1335–1340 (discussion 1340) CrossRef Letícia PSR, Canali I, Teixeira A, Silva MN, Selaimen F, da Costa SS (2010) Cholesteatoma labyrinthine fistula: prevalence and impact. Neurosurgery 67(5):1335–1340 (discussion 1340) CrossRef
4.
Zurück zum Zitat Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P (2002) True incidence of vestibular schwannoma? J Laryngol Otol 116:460–463CrossRef Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P (2002) True incidence of vestibular schwannoma? J Laryngol Otol 116:460–463CrossRef
6.
Zurück zum Zitat Tuleasca C, George M, Schiappacasse L, Patin D, Fenu J, Maire R, Levivier M (2019) Gamma Knife radiosurgery for intravestibular and intracochlear schwannomas. Acta Neurochir 161:63–67CrossRef Tuleasca C, George M, Schiappacasse L, Patin D, Fenu J, Maire R, Levivier M (2019) Gamma Knife radiosurgery for intravestibular and intracochlear schwannomas. Acta Neurochir 161:63–67CrossRef
8.
Zurück zum Zitat MacKenzie R et al (2018) The difficulty of predicting clinical outcome after intended submaximal resection of large vestibular Schwannomas. J Clin Neurosci 50:62–68CrossRef MacKenzie R et al (2018) The difficulty of predicting clinical outcome after intended submaximal resection of large vestibular Schwannomas. J Clin Neurosci 50:62–68CrossRef
9.
Zurück zum Zitat Hentschel M, Rovers M, Markodimitraki L, Steens S, Kunst H (2019) An international comparison of diagnostic and management strategies for vestibular schwannoma. Eur Arch Oto-Rhino-Laryngol 276:71–78CrossRef Hentschel M, Rovers M, Markodimitraki L, Steens S, Kunst H (2019) An international comparison of diagnostic and management strategies for vestibular schwannoma. Eur Arch Oto-Rhino-Laryngol 276:71–78CrossRef
10.
Zurück zum Zitat Bashjawish B, Kılıç S, Baredes S, Eloy JA, Liu JK, Ying Y-LM (2019) Changing trends in management of vestibular schwannoma: a national cancer database study. Laryngoscope 129:1197–1205 (The American Laryngological, Rhinological and Otological Society, Inc.) CrossRef Bashjawish B, Kılıç S, Baredes S, Eloy JA, Liu JK, Ying Y-LM (2019) Changing trends in management of vestibular schwannoma: a national cancer database study. Laryngoscope 129:1197–1205 (The American Laryngological, Rhinological and Otological Society, Inc.) CrossRef
12.
Zurück zum Zitat Myrseth E, Moller P, Pedersen PH, Lund-Johansen M (2009) Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 64(4):654–661 (discussion 661–653) CrossRef Myrseth E, Moller P, Pedersen PH, Lund-Johansen M (2009) Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 64(4):654–661 (discussion 661–653) CrossRef
13.
Zurück zum Zitat Regis J, Pellet W, Delsanti C et al (2013) Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg 119(Suppl):1091–1100 Regis J, Pellet W, Delsanti C et al (2013) Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg 119(Suppl):1091–1100
14.
Zurück zum Zitat Sagar P, Devaraja K, Kumar R, Bolus S, Sharma S (2017) Cholesteatoma induced labyrinthine fistula: is aggressiveness in removing disease justified? Indian J Otolaryngol Head Neck Surg 69:204–209CrossRef Sagar P, Devaraja K, Kumar R, Bolus S, Sharma S (2017) Cholesteatoma induced labyrinthine fistula: is aggressiveness in removing disease justified? Indian J Otolaryngol Head Neck Surg 69:204–209CrossRef
Metadaten
Titel
Middle-ear cholesteatoma co-existing with labyrinthine fistula and vestibular schwannoma
verfasst von
Aleksander Zwierz
K. Masna
P. Burduk
Publikationsdatum
23.01.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 4/2020
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-020-05796-0

Weitere Artikel der Ausgabe 4/2020

European Archives of Oto-Rhino-Laryngology 4/2020 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.